Lapatinib and trastuzumab improved OS in patients with HER2 + BC-LMD.<h4>Conclusions</h4>Increasing rates of BC-LMD provide treatment challenges and opportunities for clinical trials. This evidence concerns the gene ERBB2 and breast cancer.